TUESDAY, Oct. 29, 2024 — Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as antiobesity treatment from 2022 to 2023, with a simultaneous 25.6 percent decrease in the rate of…Original Article
Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
TUESDAY, Oct. 29, 2024 — Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as antiobesity treatment from 2022 to 2023, with a simultaneous 25.6 percent decrease in the rate of…
